Cargando…
Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers
Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcome these l...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504175/ https://www.ncbi.nlm.nih.gov/pubmed/37713009 http://dx.doi.org/10.1186/s11671-023-03897-3 |
_version_ | 1785106668245221376 |
---|---|
author | Salel, Sedef Iyisan, Banu |
author_facet | Salel, Sedef Iyisan, Banu |
author_sort | Salel, Sedef |
collection | PubMed |
description | Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcome these limitations and improve the safety and efficacy of drug delivery. The system comprises a biopolymeric shell and a lipid core, encapsulating the lipophilic anticancer drug paclitaxel. Bovine serum albumin and dextran, in various molecular weights, are covalently conjugated via Maillard reaction to form the shell which serves as a stabilizer to maintain nanoparticle integrity. The properties of the system, such as Maillard conjugate concentration, protein/polysaccharide molar ratio, and polysaccharide molecular weight, are optimized to enhance nanoparticle size and stability. The system shows high stability at different pH conditions, high drug loading capacity, and effective in vitro drug release through the trigger of enzymes and passive diffusion. Serine proteases are used to digest the protein portion of the nanoparticle shell to enhance the drug release. This nanocarrier system represents a significant advancement in the field of nanomedicine, offering a safe and effective alternative for the delivery of lipophilic drugs. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s11671-023-03897-3. |
format | Online Article Text |
id | pubmed-10504175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105041752023-09-17 Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers Salel, Sedef Iyisan, Banu Discov Nano Research Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcome these limitations and improve the safety and efficacy of drug delivery. The system comprises a biopolymeric shell and a lipid core, encapsulating the lipophilic anticancer drug paclitaxel. Bovine serum albumin and dextran, in various molecular weights, are covalently conjugated via Maillard reaction to form the shell which serves as a stabilizer to maintain nanoparticle integrity. The properties of the system, such as Maillard conjugate concentration, protein/polysaccharide molar ratio, and polysaccharide molecular weight, are optimized to enhance nanoparticle size and stability. The system shows high stability at different pH conditions, high drug loading capacity, and effective in vitro drug release through the trigger of enzymes and passive diffusion. Serine proteases are used to digest the protein portion of the nanoparticle shell to enhance the drug release. This nanocarrier system represents a significant advancement in the field of nanomedicine, offering a safe and effective alternative for the delivery of lipophilic drugs. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s11671-023-03897-3. Springer US 2023-09-15 /pmc/articles/PMC10504175/ /pubmed/37713009 http://dx.doi.org/10.1186/s11671-023-03897-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Salel, Sedef Iyisan, Banu Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title_full | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title_fullStr | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title_full_unstemmed | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title_short | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
title_sort | polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504175/ https://www.ncbi.nlm.nih.gov/pubmed/37713009 http://dx.doi.org/10.1186/s11671-023-03897-3 |
work_keys_str_mv | AT salelsedef polymerlipidhybridnanoparticlesaspotentiallipophilicanticancerdrugcarriers AT iyisanbanu polymerlipidhybridnanoparticlesaspotentiallipophilicanticancerdrugcarriers |